Core Points - Aspira Women's Health Inc. announced the departure of CEO Nicole Sandford due to family health matters, with President Dr. Sandra Milligan stepping in as interim CEO while a search for a permanent successor is conducted [1][2] - During her tenure, Sandford contributed to the launch of the OvaWatch multivariate assay and secured a $10 million award for endometriosis detection product development, positioning the company for future growth [2] - Aspira focuses on developing non-invasive, AI-powered diagnostic tests for gynecologic diseases, including ovarian cancer and endometriosis [3][5] Company Developments - The OvaSuite portfolio, which includes OvaWatch and Ova1Plus, provides comprehensive blood tests for ovarian cancer risk assessment, with OvaWatch offering a negative predictive value of 99% [4] - Aspira is expanding its ovarian cancer portfolio and developing a non-invasive test for endometriosis, aiming to enhance diagnostic sensitivity and specificity through the combination of microRNA and protein biomarkers with patient data [5]
Aspira Women's Health Announces Appointment of Dr. Sandra Milligan as Interim CEO